AstraZeneca stock: shares trade 1.43% below Xetra close
Published on 11/17/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat AstraZeneca shares signal
- AstraZeneca shares traded below the previous Xetra session's close on Tuesday afternoon.
- The quote was also lower than the level recorded in the company's preceding market report.
- Klygefa approvals in the United States and European Union remain the latest regulatory backdrop for the rare-disease business.
AstraZeneca stock traded at 165.20 euros on Lang & Schwarz at 17:13 CET on Tuesday, November 17, 2026, 1.43 percent below the Xetra close of Monday, November 16. Compared with the 168.10 euros recorded on Monday, November 16, the quote was down 1.73 percent.
Tuesday trading remains under pressure
The move leaves the shares below the previous Xetra session's close as investors assess the pharmaceutical group's latest pipeline and regulatory developments. The current quote also marks a clear step down from Monday's level.
Rare-disease approvals set context
AstraZeneca announced on November 16 that Klygefa, or gefurulimab, had received approval in the United States and the European Union for eligible adults with generalised myasthenia gravis. The treatment is administered once weekly by subcutaneous injection through an autoinjector.
The US and EU decisions were based on the PREVAIL Phase III trial. The approvals broaden the commercial reach of AstraZeneca's Alexion rare-disease unit, while further regulatory reviews remain part of the product's expansion path.
What investors watch next
Investors will focus on how the new approvals translate into commercial adoption, reimbursement and competitive positioning in the rare-disease market. The stock's position below the previous session's close keeps the market's assessment of the pipeline in focus.
The UK equity market can be followed in Current market reports.
More news and analyses on AstraZeneca stock.
AstraZeneca PLC at a glance
- ISIN: GB0009895292
- Quote: 165.20 euros on Lang & Schwarz at 17:13 CET, Tuesday, November 17, 2026
- Daily change: 1.43 percent below the Xetra close of Monday, November 16, at 167.60 euros
- Business: Biopharmaceuticals, oncology and rare diseases
- Related index: FTSE 100
